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Background & aims: The Mediterranean diet (MedDiet) is recognised to reduce risk of coronary heart disease 29 
(CHD), in part, via its anti-inflammatory and antioxidant properties, which may be mediated via effects on 30 
body fat distribution. Diet efficacy via these mechanisms is however unclear in patients with diagnosed CHD. 31 
This study aimed to determine: (1) the effect of ad libitum MedDiet versus low-fat diet intervention on 32 
adiposity, anti-inflammatory marker adiponectin, oxidative stress marker malondialdehyde (MDA) and 33 
traditional CVD risk markers, and (2) whether improvement in MedDiet adherence score in the pooled cohort 34 
was associated with these risk markers, in a pilot cohort of Australian patients post coronary event.  35 
Methods: Participants (62±9 years, 83% male) were randomised to 6-month ad libitum MedDiet (n=34) or 36 
low-fat diet (n=31). Pre- and post-intervention, dietary adherence, anthropometry, body composition (Dual-37 
energy X-ray Absorptiometry) and venepuncture measures were conducted.  38 
Results: The MedDiet group reduced subcutaneous adipose tissue (SAT) area compared to the low-fat diet 39 
group (12.5cm2 more, p=0.04) but not visceral adipose tissue or other body composition measures. In the 40 
pooled cohort, participants with greatest improvement in MedDiet adherence score had significantly lower 41 
waist circumference (-2.81cm, p=0.01) and SAT area (-27.1cm2, p=0.04) compared to participants with no 42 
improvement in score at 6-months. There were no changes in adiponectin, MDA or other risk markers in the 43 
MedDiet compared to low-fat diet group, and no differences in 6-month levels between categories of 44 
improvement in MedDiet score (p>0.05). Within the MedDiet group only, the proportion of participants taking 45 
beta-blocker medication reduced from baseline to 6-months (71% vs. 56%, p-trend=0.007).  46 
Conclusions: Adherence to 6-month ad libitum MedDiet reduced subcutaneous fat and waist circumference 47 
which discounts the misconception that this healthy but high fat diet leads to body fat gain. The effect of 48 
MedDiet on body fat distribution and consequent anti-inflammatory and antioxidant effects, as well as need 49 
for medications, in patients with CHD warrants exploration in larger studies. Clinically significant effects on 50 
these markers may require adjunct exercise and/or caloric restriction. 51 
Trial registration: ACTRN12616000156482.  52 
 53 






1. Introduction  57 
 58 
The Mediterranean diet (MedDiet) pattern has a strong scientific evidence base for reducing risk of coronary 59 
heart disease (CHD) and adverse cardiovascular disease (CVD) events (1, 2). Nonetheless, the majority of 60 
studies investigating the MedDiet have been conducted in Mediterranean countries. A low-fat diet was the 61 
standard care recommendation for prevention and treatment of CHD in Australia for many years (3), however,  62 
a recent position statement from the National Heart Foundation of Australia promotes a variety of healthy 63 
dietary patterns, rather than focusing on isolated nutrients, for cardiovascular health (4). 64 
 65 
Atherosclerosis is the underlying pathology responsible for CHD. Derangements in lipid levels, blood pressure 66 
and insulin homeostasis each lead to endothelial dysfunction, which plays a pivotal role in initiating the 67 
atherosclerotic process (5). A number of studies, including in the Australian setting, have demonstrated that 68 
the MedDiet improves CVD risk factors, including improvements in triglycerides and high-density lipoprotein 69 
(HDL) cholesterol, blood pressure, glucose metabolism and reduced risk of type 2 diabetes mellitus (T2DM) 70 
(6-13). These studies were conducted in patients at risk of, but without, established CHD. In CHD, especially 71 
in those who have suffered acute coronary syndrome (ACS), pharmacotherapy is used to achieve recommended 72 
lipid, glucose and blood pressure targets (14), hence the possibility to attain additional impact of diet on these 73 
risk factors may not be observed in these patients. In fact, the limited published data on the impact of MedDiet 74 
on secondary prevention of ACS demonstrated that the diet may be operating independently of traditional CVD 75 
risk factors (1).   76 
 77 
Atherosclerosis is recognised to be an inflammatory condition, which is related to both the chronic 78 
development of plaque and its acute rupture (15). In addition, obesity, especially increased visceral fat, is 79 
causally linked to chronic low-grade inflammation (16, 17). In an obese state, adipose tissue generates pro-80 
inflammatory adipokines, including interleukin-6 (IL-6), whereas anti-inflammatory adipokines, including 81 
adiponectin, are down-regulated (18). High serum concentrations of adiponectin are associated with decreased 82 




patients with CHD, through increased oxidation of LDL particles and endothelial dysfunction (21). Plasma 84 
malondialdehyde (MDA), a non-invasive measure of lipid peroxidation, is a recognised marker of oxidative 85 
stress and elevated MDA levels are reported in patients with CHD (22). 86 
 87 
To better understand how dietary interventions moderate CHD risk, it is important to ascertain their effect on 88 
novel markers such as adiposity, inflammation and oxidative stress in addition to classic cardiometabolic risk 89 
markers. A recent review of intervention trials demonstrated that the MedDiet can reduce central obesity; 90 
however, most studies measured waist circumference without distinguishing visceral and subcutaneous fat and 91 
included patients without CHD (23). Meta-analyses of randomised controlled trials (RCTs) have also 92 
concluded that intervention with the MedDiet improves a range of established inflammatory and oxidative 93 
stress markers (24, 25). However, a recent systematic review of the literature established that no studies have 94 
investigated the effect of MedDiet on adiponectin in patients with diagnosed CHD (26). Moreover, with respect 95 
to lipid peroxidation, MedDiet intervention improved MDA levels in patients at risk of but without CHD (27).  96 
 97 
We have previously reported results from this pilot MedDiet intervention, showing no improvement in the 98 
inflammatory markers high sensitivity C-Reactive Protein (hs-CRP) or hs-IL-6, despite significant 99 
improvement in MedDiet adherence and dietary anti-inflammatory potential (measured by the dietary 100 
inflammatory index) in Australian patients who have experienced an ACS event (28, 29). Therefore, the 101 
primary aim of the present analysis was to determine the effect of ad libitum MedDiet versus low-fat diet 102 
intervention on additional cardiometabolic risk markers, including compartmental adiposity, anti-103 
inflammatory marker adiponectin, and MDA levels in the same pilot cohort. A secondary aim was to determine 104 
whether improvement in MedDiet adherence score in the pooled cohort was associated with resultant 105 
improvement in risk marker levels. Results from this pilot will be used to inform feasibility and sample size 106 
requirements for future analyses.  107 
 108 
2. Materials and Methods  109 
 110 




The data reported in this study was collected in the pilot of the AUStralian MEDiterranean Diet Heart Trial 112 
(AUSMED Heart Trial), a multi-centre, parallel design, randomised controlled trial (RCT) of 6-month 113 
MedDiet versus low-fat diet intervention for the secondary prevention of CHD at 12-months in a multi-ethnic 114 
Australian population (Australia and New Zealand Clinical Trials Register: ACTRN12616000156482) (30). 115 
As noted above, this pilot study and methodology, including results for nutritional intake and diet quality (29), 116 
the dietary inflammatory index, hs-CRP and hs-IL-6 (28, 31) has previously been reported.  117 
 118 
2.2 Recruitment of CHD Patients 119 
Patients for this pilot study were recruited from two tertiary hospitals in Melbourne, Australia between October 120 
2014 and November 2016. Eligible patients were adults with CHD, able to read and write in English and who 121 
had experienced ACS defined as at least one of the following: acute myocardial infarction (AMI); angina 122 
pectoris with documented coronary artery disease on imaging; coronary artery bypass grafting; or percutaneous 123 
coronary intervention. The study was conducted in accordance with the Declaration of Helsinki (32) and the 124 
CONSORT guidelines (33). All procedures involving patients were approved by the Human Research Ethics 125 
Committees of The Northern Hospital, St Vincent’s Hospital Melbourne, and La Trobe University, with 126 
written informed consent obtained from all enrolled participants before randomisation. 127 
 128 
2.3 Randomisation of Participants and Diet Interventions 129 
At a pre-baseline appointment, enrolled participants were randomly assigned in a 1:1 ratio to the MedDiet 130 
group or the low-fat diet group using a stratified approach (based on sex, age and prior AMI). Baseline, 3- and 131 
6-month face-to-face appointments were conducted to obtain dietary data and for counselling with the dietitian. 132 
Five short phone reviews for follow-up dietary counselling with the dietitian also occurred across the 6-months, 133 
at weeks 3, 6, and 9 and months 4 and 5. Both diets were prescribed ad libitum with no specific 134 
recommendations on energy restriction. All participants continued to receive standard medical care provided 135 
at their respective hospital or primary care settings and their access to outside health services during the study 136 
intervention period was recorded at each appointment.  137 
 138 




The rationale, development and resources provided with our MedDiet intervention, designed for use in chronic 140 
disease intervention trials in the Australian setting (30, 34), has been explained and published in detail 141 
elsewhere (35). Briefly, the diet was modelled via a 2-week meal plan which incorporated key dietary 142 
components of a MedDiet and a mix of traditional and modified recipes considered to be realistic options in 143 
the multi-ethnic Australian setting. Food group recommendations included: daily intake of extra virgin olive 144 
oil (EVOO), wholegrain cereals, vegetables, fruit and nuts; regular intake of fish and seafood, legumes and 145 
yoghurt; and limited intake of commercial sweets or pastries and red or processed meat. Poultry, eggs and feta 146 
cheese were recommended in moderation. For existing alcohol drinkers, red wine was suggested to be 147 
consumed in moderation (1-2 standard glasses) with meals. To facilitate dietary compliance and to encourage 148 
intake of staple Mediterranean foods less familiar to this Australian population, a hamper was provided to 149 
participants at baseline and 3-months, including 6L EVOO (to achieve 60-80mL/day) and 1.2kg nuts (almonds, 150 
walnuts and hazelnuts to achieve 30g/day).  151 
 152 
2.3.2 Low-fat Diet 153 
Participants in the low-fat diet group were instructed to follow the standard diet recommendations provided to 154 
cardiac patients in Australia at the time this study was developed (in 2014). Recommendations from the 155 
National Heart Foundation (3) and Australian Dietary Guidelines (36, 37) were consulted for design of the 156 
low-fat diet. Food group recommendations included daily intake of grains and cereals (mostly whole grains), 157 
vegetables, lean meats and alternatives, fruit, and low-fat dairy foods (36). Participants were provided with a 158 
supermarket voucher at each of their three face-to-face appointments to aid compliance and encourage 159 
continuation in the trial.  160 
 161 
2.4 Study Measures 162 
This study reports on outcome measurements collected at the baseline and 6-month appointments. Data on 163 
medical conditions was collected from medical records and in consultation with hospital staff during the 164 
screening process, and via a questionnaire at the pre-baseline appointment. Participants completed a self-report 165 




characteristics, including medication and supplement use. A modified version of the survey was completed at 167 
both 3- and 6-month appointments, which re-assessed lifestyle and clinical characteristics. 168 
 169 
2.4.1 Dietary Intake 170 
The week prior to each face-to-face appointment the participants completed a 7-day food diary which was 171 
entered into FoodWorks (Version 8, Xyris software Australia Pty Ltd) for nutrient and food group intake 172 
analyses. The 14-point Mediterranean Diet Adherence Screener (MEDAS), generated and validated for the 173 
PREDIMED study (38), was measured at each appointment for both diet study groups.  174 
 175 
2.4.2 Cardiometabolic Risk Markers  176 
Our methods for assessment of activity levels, anthropometry, body composition, blood pressure and pathology 177 
measures have also been described previously (31). Increased physical activity was not a target of this 178 
intervention, however, physical activity levels were assessed to account for any potential confounding effects 179 
on outcome markers. Participants wore a triaxial Actigraph accelerometer (WGT3X-BT; Actigraph Corp, 180 
Florida, United States) for one week prior to their appointments. Established criteria (39) were used to 181 
determine time spent as min /week in moderate-to-vigorous physical activity (MVPA) or as sedentary time. 182 
Weight, height and waist circumference measures were performed according to the International Society for 183 
the Advancement of Kinanthropometry (ISAK) standards for anthropometric assessment (40). Whole body 184 
composition was measured using a fan beam densitometer Dual-energy X-ray Absorptiometry (DXA) machine 185 
(Hologic, Discovery W, USA), with analysis performed using QDR™ (Quantitative Digital Radiography) for 186 
Windows. Measurements obtained from each scan were total body lean and fat mass, total body and regional 187 
fat percentage, subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) areas. Hologic scientists 188 
developed their method for measuring VAT from DXA (41), which is highly correlated (r=0.93) and linearly 189 
related to VAT measurements by computed tomography (42). Fat mass index (FMI) was calculated by dividing 190 
the total body fat mass (kg) by height (m) squared (43). Systolic blood pressure (SBP), diastolic blood pressure 191 
(DBP) and heart rate (HR) were measured using an automated blood pressure monitor (OMRON Tp9, 192 
IntellisenSense, Australia). Hypertension (presence or history of) was classified based on whether the 193 




inhibitor, angiotensin 2 receptor blocker, Beta [β]-blocker or Ca2+ channel blocker) and/or mean baseline blood 195 
pressure reading of SBP >140 mmHg or DBP >90 mmHg (44). Diagnosis of T2DM was determined by 196 
consulting participant medical history records. 197 
 198 
Fasting blood samples were taken by venepuncture and processed immediately into serum/plasma aliquots (as 199 
published in detail elsewhere (45)) which were stored at -80 °C until laboratory assays were conducted. Serum 200 
low-density lipoprotein (LDL) cholesterol, HDL cholesterol, triglycerides and hs-CRP levels were measured 201 
at a commercial laboratory (Dorevitch Pathology Pty Ltd, Heidelberg, Australia). Other biomarker measures 202 
were performed by trained personnel at La Trobe University, except for MDA which was performed at the 203 
University of Newcastle. Enzyme‐linked immunosorbent assay (ELISA) kits were used to measure serum hs-204 
IL-6 levels (Abcam Australia Pty Ltd, #ab46042), serum adiponectin levels (Invitrogen, Thermofisher 205 
Scientific, #KHP0041) and plasma MDA levels (Abcam Australia Pty Ltd, #ab118970). Fasting serum glucose 206 
levels were measured using the enzymatic hexokinase method by a chemical analyser (Indiko, Thermofisher 207 
Scientific). Personnel performing laboratory analyses were blinded to study group allocation of samples. 208 
 209 
2.5 Statistical Analyses  210 
This study represented a preliminary analysis in a pilot cohort and therefore a sample size calculation was not 211 
performed prior to conducting the measures (46). The broader AUSMED Heart Trial is powered to detect a 212 
significant effect of MedDiet on secondary cardiovascular endpoints and will recruit 1000 participants (30). 213 
All statistical analyses were conducted in SPSS® statistical package version 25 (IBM Corp, released 2015). 214 
Statistical significance was set at p<0.05. Data are presented as means ± standard deviation (SD) or standard 215 
error (SEM), medians (interquartile range [IQR]) or n (%), as appropriate. The Kolmogorov–Smirnov test was 216 
applied to assess the normality of continuous variables. According to this, an Independent Student’s t-test or 217 
non-parametric Mann-Whitney U test was used to compare continuous variables. Categorical variables were 218 
compared using the Chi-square test.  219 
 220 
All outcome measures were analysed based on intention-to-treat with missing data included by bringing 221 




proportion of participants taking medication and supplement classes from baseline to 3- and 6-months within 223 
each study group. Repeated measures ANOVA (analysis of variance) assessed changes in cardiometabolic risk 224 
marker variables from baseline to 6-months between groups. Measures which were non-parametric were log 225 
transformed to improve their distribution. The main ANOVA results assessed for effect were (1) group 226 
(significant change in one study group compared to the other) and (2) time (significant change in pooled study 227 
groups). Post-hoc tests were performed to determine within-group changes (Paired Samples t-test). Analyses 228 
for all risk markers were adjusted for change in MVPA and haemodynamic and pathology measures were 229 
additionally adjusted for baseline BMI. The repeated measures analysis inherently controlled for participant 230 
characteristics not subject to change and were not different between study groups at baseline, including sex 231 
and T2DM status. The between-group findings for adiponectin and MDA levels were used to perform a sample 232 
size calculation to inform future analyses (described in Results).   233 
 234 
To account for any cross-over in improvement towards the MedDiet pattern in participants of the low-fat diet 235 
group, analyses were also performed in the pooled cohort (with inclusion of hs-CRP and hs-IL-6 which have 236 
not previously been analysed in this way). Tertiles of change in participant MEDAS scores from baseline to 237 
6-months were created in SPSS. Least-squared means (95% confidence interval [CI]) of cardiometabolic risk 238 
markers at 6-months were estimated across the tertiles of MEDAS change. Multi-variable general linear 239 
models adjusted for baseline value, sex, age, T2DM, time since coronary event and change in MVPA were 240 
used to estimate the differences in means across tertiles. For hs-CRP, participants with serum levels >10 mg/L 241 
were excluded from analyses, as these higher concentrations reflect acute rather than chronic inflammation 242 
(48). 243 
 244 
3. Results 245 
 246 
3.1 Participants 247 
Randomisation to diet study groups, completion of study appointments and number and reasons for withdrawal 248 
have been reported elsewhere (28, 29). Briefly, of 73 randomised participants, 65 attended a baseline 249 




dropping out from the low-fat diet and MedDiet groups respectively. Participants were lost to follow up (n=2) 251 
or discontinued due to relocation (n=2), non-cardiac medical problems (n=3) or family related issues (n=2).  252 
There were no significant differences for sociodemographic or clinical characteristics between those 253 
participants that dropped out compared to completers.  254 
 255 
As reported in Table 1, the cohort represented a mostly male, middle to late aged group of which close to half 256 
were born outside Australia (18% were born in the Mediterranean region). Participants had highly variable 257 
levels of MVPA (total range 3 to 665 min /week), their baseline MedDiet adherence was low (mean MEDAS 258 
score of 5 out of 14) and 80% had previously attended a cardiac rehabilitation program. Most participants had 259 
experienced an AMI and undergone percutaneous coronary intervention with a median time since ACS event 260 
of <6 months prior. Close to one third had diagnosed T2DM and nearly all had current or previous 261 
hypertension. Participants were prescribed multiple medications, of which anti-platelets and statins (both 262 
>90%) were the most common (Supplementary Materials, Table S1). Close to half the participants were taking 263 
nutrition supplements, of which vitamin D (19%) and omega-3 (15%) were the most common (Table S1). 264 
There were no significant differences at baseline between the diet study groups for any of these reported 265 
sociodemographic, lifestyle or clinical characteristics.  266 
 267 
Table 1. Participant baseline characteristics in the study groups 268 
Characteristic Low-fat (n=31) MedDiet (n=34) 
Sociodemographic    
Male  27 (87.1) 27 (79.4) 
Age (years) 61.8 ± 9.5 61.8 ± 9.2 












Lifestyle   




>100 cigarettes in lifetime 18 (58.1) 20 (58.8) 
BMI (kg/m2) 29.1 ± 5.3 30.7 ± 5.0 
MVPA (min /week)†  120.0 (189.5) 153.0 (210.0) 
MEDAS (score out of 14)  4.8 ± 1.8 5.6 ± 2.2 
Cardiac rehabilitation  26 (83.9) 25 (73.5) 
Medical History    
Acute myocardial infarction  
Percutaneous coronary intervention 
Coronary artery bypass grafting  









Type 2 diabetes mellitus  
Hypertension  







Values are n (%), Mean ± SD or Median (IQR)†. MedDiet; Mediterranean diet; BMI, body mass index; MVPA, 269 
moderate-to-vigorous physical activity; MEDAS, Mediterranean diet adherence screener.  270 
 271 
There were no significant differences between the groups for frequency of attendance at each of the study 272 
appointments and phone call reviews conducted across the diet intervention period (Supplementary Material, 273 
Table S2). The proportion of participants who attended each of the appointments or reviews was 80% or more. 274 
The participants reported having accessed a variety of other health services during the intervention period, but 275 
there were no significant differences between the study groups (Table S2). There was a reduction in the 276 
proportion of participants prescribed β-blockers in the MedDiet group between baseline and at 3-months (from 277 
24 to 19 participants) and this was maintained at 6-months (p-trend=0.007). There were no other changes in 278 
the proportion of participants taking prescribed medications in either study group (Table S1). Participants 279 
reported high medication compliance at baseline and this remained consistent throughout the study. There were 280 
no significant changes within either study group for use of nutrition supplements across the intervention period 281 
(Table S1). 282 
 283 




Daily intake of food group serves, energy and nutrients have been reported previously (29). Briefly, in 285 
the MedDiet group, in line with recommendations, consumption of olive oil, fruit, yoghurt, nuts, legumes and 286 
seafood significantly increased, whereas red and processed meats decreased after 6-months. There were no 287 
significant changes for dietary intake of individuals nutrients or foods in the low-fat diet group. There was a 288 
significantly greater improvement in mean MEDAS score in the MedDiet group (+4.8 points from a baseline 289 
score of 5.6 out of 14) compared to low-fat diet group (+1.2 points from a baseline of 4.8 out of 14) (p<0.001). 290 
The small improvement in MedDiet score in the low-fat diet participants was related to their improved 291 
adherence to score components for vegetable intake and use of butter/cream. There was no significant 292 
difference for change in MEDAS score between participants born in a Mediterranean country versus not, as 293 
assessed separately within the study groups and with the study groups pooled. No participants reported harmful 294 
side effects or adverse events directly related to the dietary interventions. 295 
 296 
3.3 Activity Levels  297 
There were no significant changes in time spent as sedentary or in MVPA activity between baseline and 6-298 
months in the MedDiet or low-fat diet groups (Table 2, all variables reported as mean ± SEM). However, there 299 
was a high level of individual variability for these measures and participants in the MedDiet group tended to 300 
reduce their MVPA level (by 42 min /week, p=0.20), hence this justified controlling for any activity changes 301 
in the risk marker analyses. 302 
 303 
3.4 Anthropometry and Body Composition  304 
With regards to anthropometry and body composition measures, there was a significant between-group 305 
difference for 6-month change in SAT area only (-12.1 ± 6.5 cm2 in the MedDiet vs. +0.4 ± 6.9 cm2 in the low-306 
fat diet group, p=0.04; Figure 1). VAT area did not change within the MedDiet (-0.1 ± 3.8 cm2) or the low-fat 307 
diet (+2.4 ± 4.0 cm2) groups (p=0.58, Figure 1). There were no significant within-group changes for weight, 308 
BMI, waist circumference, or waist-hip ratio (Table 2). There was no significant reduction in waist 309 
circumference over time in the pooled study groups (-1.1 cm, p=0.07 within the MedDiet and -0.4 cm, p=0.52 310 
within in the low-fat diet group). There was also no significant reduction in total body fat % over time in the 311 




Leg fat %, however, decreased significantly over time in the pooled study groups (p=0.04) with a significant 313 
reduction within the MedDiet group (-0.6%, p=0.03) but not the low-fat diet group (-0.5%, p=0.10).  314 
 315 
 316 
Figure 1. Subcutaneous and visceral adipose tissue measured by dual energy x-ray absorptiometry at 317 
baseline and end-intervention in the MedDiet and low-fat diet groups. Data are mean ± SEM with 318 
adjustment for change in moderate to vigorous physical activity levels. MedDiet, Mediterranean diet. 319 
*Significant reduction in MedDiet compared to low-fat diet participants, p=0.04.  320 
 321 
3.5 Haemodynamic, Cholesterol and Glucose Measures 322 
There were no between-group changes for any of the reported haemodynamic, cholesterol or glucose markers, 323 
adjusted for MVPA change and baseline BMI (Table 2). There was a significant reduction in resting HR in the 324 
pooled study groups (p=0.03), with a trend for greater reduction in the MedDiet (-1.5 bpm, p=0.07) compared 325 
to the low-fat diet (-0.8 bpm, p=0.55) group. With regards to lipids, the only significant within-group finding 326 




diet group. There were no changes within either study group for triglycerides or fasting glucose levels (also 328 
assessed separately for T2DM status).  329 
 330 
3.6 Adiponectin  331 
There were no between-group changes for serum levels of the anti-inflammatory marker adiponectin (p=0.45) 332 
adjusted for MVPA change and baseline BMI (Table 2). There was also no significant change in adiponectin 333 
between baseline and 6-months within the low-fat diet (-0.91 ng/mL, p=0.23) or MedDiet (+1.10 ng/mL, 334 
p=0.37) groups. Data from this interim analysis on the 6-month between-within group changes for adiponectin 335 
were used to perform a reverse sample size calculation in statistical software program G*Power 3.1.94 (49). 336 
Based on the study group effect size (derived from the partial eta2 of the repeated measures group comparison) 337 
of 0.101, and a correlation value between adiponectin levels at baseline and 6-months of r=0.689 at 80% power 338 
and α<0.05, a sample size of 124 participants would be required to detect a significant effect of the MedDiet 339 
on adiponectin compared to the low-fat diet.  340 
 341 
3.7 Malondialdehyde  342 
There were no between-group changes for plasma MDA levels (p=0.75) adjusted for MVPA change and 343 
baseline BMI (Table 2). There was also no significant change in MDA levels between baseline and 6-months 344 
within the low-fat diet (+0.02 nmol/mL, p=0.93) or MedDiet (-0.25 nmol/L, p=0.24) groups. MDA data were 345 
also used to perform a sample size calculation as above. Based on the study group effect size of 0.045 and a 346 
correlation value between MDA levels at baseline and 6-months of r=0.775, a sample size of 444 participants 347 











Table 2. Cardiometabolic risk markers at baseline and end-intervention in the study groups 356 
Marker Low-fat diet (n=31) MedDiet (n=34) p-value  
 Baseline 6-month Baseline 6-month Group Time 





148 ± 27 
 
3431 ± 138 
135 ± 21 
 
3477 ± 133 
186 ± 26 
 
3380 ± 135 







Anthropometry       
Weight (kg) 85.0 ± 3.3 84.7 ± 3.3 89.1 ± 3.2 89.1 ± 3.1 0.36 0.51 
Body mass index (kg/m2) 29.0 ± 0.9 28.9 ± 0.9 30.8 ± 0.9 30.8 ± 0.9 0.15 0.58 
Waist circumference (cm) 101.9± 2.6 101.5 ± 2.5 104.5 ± 2.5 103.4 ± 2.4 0.53 0.07 
Waist-hip ratio 0.976 ± 0.02 0.973 ± 0.01 0.977 ± 0.01 0.966 ± 0.01 0.89 0.10 
Body composition       
Total lean (kg) 55.6 ± 2.0 55.9 ± 2.0 56.1 ± 1.0 56.6 ± 1.9 0.83 0.22 
Total fat (kg) 27.7 ± 1.8 27.2 ± 1.7 31.1 ± 1.7 30.6 ± 1.6 0.16 0.11 
Fat mass index (kg/m2) 9.45 ± 0.6 9.42 ± 0.6 10.84 ± 0.5 10.68 ± 0.6 0.10 0.42 
Total fat % 32.7 ± 1.2 32.3 ± 1.3 35.3 ± 1.1 34.7 ± 1.2 0.13 0.05 
Trunk fat % 34.9 ± 1.2 34.6 ± 1.3 37.9 ± 1.1 37.3 ± 1.2 0.10 0.08 
Arm fat % 32.7 ± 1.6 32.2 ± 1.7 36.2 ± 1.5 35.8 ± 1.6 0.12 0.21 
Leg fat % 30.6 ± 1.4 30.1 ± 1.5 32.6 ± 1.3 32.0 ± 1.4a 0.31 0.04* 
Haemodynamic       
SBP (mmHg) 140.6 ± 3.3 139.5 ± 2.8 133.4 ± 3.1 132.0 ± 2.6 0.07 0.84 
DBP (mmHg) 83.3 ± 1.6 83.0 ± 1.6 81.0 ± 1.5 80.6 ± 1.5 0.25 0.09 
HR (bpm) 66.9 ± 2.0 66.1 ± 2.0 68.5 ± 1.9 66.0 ± 1.9 0.77 0.03* 
Pathology       
LDL (mmol/L)† 1.73 ± 0.13 1.95 ± 0.15a 1.96 ± 0.13 1.99 ± 0.15 0.48 0.35 
HDL (mmol/L)† 1.20 ± 0.05 1.24 ± 0.05 1.21 ± 0.05 1.25 ±0.05 0.83 0.47 
Triglycerides(mmol/L)† 1.35 ± 0.13 1.30 ±0.14 1.57 ± 0.12 1.60 ± 0.13 0.12 0.65 
Glucose (mmol/L) 
  No T2DM (n=44) 
5.27 ± 0.26 
4.92 ± 0.16 
5.18 ± 0.27 
4.78 ± 0.12 
5.76 ± 0.25 
4.98 ± 0.15 
5.65 ± 0.26 









Adiponectin (ng/mL)† 8.40 ± 0.71 7.49 ± 0.83 8.36 ± 0.68 9.47 ± 0.81 0.45 0.65 
Malondialdehyde (nmol/mL)  6.96 ± 0.31 6.98 ± 0.33 6.96 ± 0.30 6.71 ± 0.32 0.75 0.11 
Values are Mean ± SEM with anthropometry/body composition adjusted for MVPA change, and 357 
haemodynamic/pathology markers adjusted for MVPA change and baseline BMI. One low-fat diet participant did 358 
not consent to DXA scan and was excluded from body composition analyses. One MedDiet participant who dropped 359 
out and had haemolysed blood sample at baseline was excluded from pathology marker analyses. MedDiet, 360 
Mediterranean diet; MVPA; moderate to vigorous physical activity; SBP; systolic blood pressure; DBP, diastolic 361 
blood pressure; HR, heart rate; LDL, low-density lipoprotein; HDL, high-density lipoprotein; T2DM, type 2 diabetes 362 
mellitus; †Non-parametric, analyses based on transformed variable. ‡One participant with T2DM had a major 363 
increase in insulin dosage and was excluded from analyses. Significant, p<0.05, for: *Main effect of group or time; 364 
adifference between baseline and 6-months for that group.  365 
 366 
3.8 Association Between Mediterranean Diet Adherence and Risk Markers 367 
All participants were categorised into tertiles of change in MEDAS score from baseline to 6-months. This 368 
resulted in tertile 1 (T1) of -2 to +1, tertile 2 (T2) of +2 to 5, and tertile 3 (T3) of +6 to 9. As expected, in T3, 369 
with the largest 6-month improvement in MedDiet adherence, 93% of participants were from the MedDiet 370 
group. In T2 and T1 the proportion of participants in the MedDiet group was 56% and 22%, respectively. Mean 371 
(95% CI) levels for cardiometabolic risk markers at 6-months, adjusted for baseline value, sex, age, T2DM, 372 
time since coronary event and change in MVPA, are presented in Table 3. For each of the reported 373 
anthropometric, body composition and hemodynamic measures the mean value decreased across tertiles from 374 
T1 to T3 (from lowest to greatest MEDAS score improvement), except for VAT area and DBP, which had a 375 
higher mean value in T2, followed by T1 and then T3. Compared to T1, T3 participants had a significantly 376 
lower mean waist circumference (-2.81 cm, p=0.01), waist-hip ratio (-0.022, p=0.047) and SAT area (-27.4 377 
cm2, p=0.04). Mean levels of other pathology markers did not demonstrate any consistent trends across tertiles. 378 
For adiponectin, the mean value increased slightly but with no significant difference across tertiles from lowest 379 
to greatest MEDAS score improvement (+0.68 ng/mL from T1 to T3, p=0.50). There was also no difference 380 





Table 3. Adjusted means of cardiometabolic risk markers at 6-months by tertiles of change in 383 
Mediterranean Diet Adherence Screener (MEDAS) scorea 384 
Marker 
Tertile 1 (-2 to +1 points) 
n=22 
Tertile 2 (+2 to 5 points) 
n=27 













Weight (kg)†  
Body mass index (kg/m2) 
































Body composition  
Fat mass index (kg/m2) 
Total body fat (%) 








































SBP (mmHg)  
DBP (mmHg) 





























LDL (mmol/L)  
HDL (mmol/L) 
Triglycerides (mmol/L)  
Glucose (mmol/L)‡  
hs-CRP (mg/L)**  
hs-IL-6 (pg/mL)  
Adiponectin (ng/mL) 























































T, tertile; CI; confidence interval; VAT visceral adipose tissue; SAT, subcutaneous adipose tissue; SBP, systolic blood 385 
pressure; DBP, diastolic blood pressure; HR, heart rate; LDL, low-density lipoprotein; HDL, high-density lipoprotein; 386 
hs-CRP, high sensitivity C-reactive protein; hs-IL-6, high sensitivity interleukin-6. aAdjusted average indices as least-387 
square means with 95%CI adjusted for baseline value, sex, age, type 2 diabetes mellitus, time since coronary event 388 
and change in moderate-to-vigorous activity levels. *Significant difference between T1 and T3, p<0.05. †Variable 389 
log-transformed and data are presented as adjusted geometric means and confidence intervals have been backwards 390 
logged, except for MDA. ‡One participant with T2DM had a major increase in insulin dosage and was excluded from 391 
analyses. **Two participants excluded for value >10mg/L.  392 
 393 
 394 
4. Discussion 395 
 396 
This study has reported on the effect of a 6-month intervention with ad libitum MedDiet versus low-fat diet on 397 




CHD. The results demonstrated that the MedDiet significantly reduced SAT but not VAT area compared to 399 
the low-fat diet. Despite significantly improved adherence to the Mediterranean dietary pattern (29), there was 400 
no significant effect of the MedDiet on adiponectin, MDA or classic CVD risk markers of lipids, glucose or 401 
blood pressure compared with the low-fat diet. Notable within group findings were a reduction in the 402 
proportion of MedDiet participants prescribed β-blockers and increased LDL cholesterol levels in the low-fat 403 
diet group. Across tertiles of increasing improvement in MedDiet adherence score in the pooled study cohort 404 
at 6-months, a significantly lower waist circumference, WHR and SAT area was observed. 405 
 406 
The significant improvement in the SAT but not the VAT area following MedDiet compared to the low-fat 407 
diet was unexpected. Two previous studies (50, 51) reported a significant reduction in markers of VAT 408 
(measured by bioelectrical impedance analysis or ultrasound) following MedDiet intervention. One of these 409 
studies also demonstrated that MedDiet intervention did not significantly impact subcutaneous fat (50). Both 410 
previous interventions employed energy restrictions and were conducted in patients without CVD, which may 411 
explain why no reduction in VAT was observed in the current study of an ad libitum MedDiet and the first in 412 
CHD patients. The reduction in subcutaneous fat in the present study is contradictory to previous findings that 413 
intake of MUFA (which AUSMED participants substantially increased) favours deposition as subcutaneous 414 
rather than visceral fat (52). The lack of improvement in VAT with our MedDiet intervention assists to explain 415 
the lack of significant effect on inflammatory markers given VAT represents more metabolically dysfunctional 416 
tissue (16, 17). There is an established protective effect of exercise on visceral fat (53) and chronic 417 
inflammation in patients with CHD (54). Therefore, whilst changes in MVPA were controlled for, it cannot be 418 
ruled out that a lack of improvement in VAT area and inflammatory biomarkers was related to an observed 419 
reduction in MVPA levels in some MedDiet participants.  420 
 421 
The maintenance of weight and trend for reduction in total body fat in the MedDiet group occurred despite the 422 
tendency of the group to increase total energy intake (29). These findings assist to discount the belief that the 423 
high healthy fat MedDiet is associated with weight and fat gain (55) and could be related to the high content 424 
of unsaturated fats, particularly MUFA and omega-3 PUFA, in the MedDiet. These unsaturated fats have been 425 




Australian patients with T2DM (n=27) a 12-week ad libitum MedDiet intervention resulted in a small reduction 427 
in body weight, despite significantly increased energy and MUFA intake (13).    428 
 429 
This is the first study to examine the effect of MedDiet on the anti-inflammatory marker adiponectin in patients 430 
with diagnosed CHD. No significant change was detected in this pilot cohort, with only a trend for reduction 431 
in the MedDiet compared to low-fat diet group observed. Adiponectin has been reported in previous MedDiet 432 
intervention studies that have been conducted in subject groups without CHD diagnosis. In a study of pre-433 
menopausal obese women adiponectin increased with a calorie-restricted MedDiet compared to general 434 
diet/exercise advice (58). A sub-study of the PREDIMED trial in patients with T2DM also demonstrated an 435 
increase in plasma adiponectin, but this increase occurred with all three (Mediterranean + EVOO, 436 
Mediterranean + Nuts and low-fat) diet interventions; mean weight loss was significant but less than 1kg in 437 
each group (9). It was also found that a MedDiet in the absence of weight loss can significantly reduce 438 
inflammation (composite score of CRP, IL-6 and tumour necrosis factor-α) (59) but not levels of adiponectin 439 
(60). The DIRECT study, which included a MedDiet intervention with 6-month weight loss phase followed by 440 
an 18-month weight maintenance phase, demonstrated a continued significant increase in adiponectin for the 441 
duration of the trial (61). Most of these findings suggest that a significant increase in adiponectin with MedDiet 442 
is dependent on concomitant weight loss (at least initially), which helps to explain the lack of significant effect 443 
on adiponectin in the current study with an ad libitum approach. Our results estimated that without weight loss 444 
(and no change in VAT), twice the sample size would be required to demonstrate a significant improvement 445 
in adiponectin with MedDiet compared to low-fat diet. 446 
 447 
This was one of first studies to examine the effect of a dietary intervention on oxidative stress marker plasma 448 
MDA in patients with CHD and no significant effect of the MedDiet compared to low-fat diet was found. 449 
Similarly, a previous study of MedDiet intervention versus control (habitual) diet in patients with Rheumatoid 450 
Arthritis and on stable pharmacological treatment (n=51) demonstrated no effect on MDA levels in urine (62). 451 
A preliminary study in a subset of PREDIMED participants (n=71), at high risk of but without CHD, did 452 
demonstrate a significant improvement in MDA with 3-month MedDiet versus low-fat diet (27). However, 453 




our study) and the changes in MDA paralleled improvements in oxidised LDL levels. Recent meta-analysis 455 
also demonstrated evidence to support that consumption of extra virgin olive oil reduces MDA levels, however, 456 
the four intervention studies each prescribed ~70 g oil per day and were conducted in healthy adults (63).  457 
 458 
Of particular interest, a significant number of MedDiet participants (15%) stopped taking β-blocker medication 459 
during the trial. Despite cessation of this antihypertensive medication, for the MedDiet cohort no significant 460 
change in mean SBP, DBP or HR was detected. A potential reduction in need for this medication with the 461 
MedDiet is a promising finding as β-blockers have a range of short and long-term side effects (44). This finding 462 
warrants for the effect of the MedDiet on cardiac medication to be investigated further. The present study also 463 
demonstrated no significant effect of the MedDiet on LDL cholesterol, triglycerides or glucose, compared to 464 
the low-fat diet. These results were not unexpected considering that most participants were prescribed statins 465 
or other lipid-lowering therapy as well as anti-hypertensives, and nearly all participants with T2DM were 466 
taking hypoglycaemic agents. Interestingly, the low-fat diet group significantly increased LDL cholesterol 467 
levels after 6-months. This contradicts the premise of the low-fat diet, which was designed to lower LDL 468 
cholesterol levels. This finding may be reflective of the lack of improvement in adherence to the low-fat diet 469 
principles seen in that group, and their slight increase in saturated fat intake (29).  470 
 471 
Our study had a number of strengths. The intensity of the dietary counselling was the same in both groups to 472 
control for this effect. In both study groups the focus of the intervention was dietary improvement only and 473 
the approach was ad libitum in order to isolate the effect of diet rather than changes in weight loss or improved 474 
physical activity. The secondary analyses in the pooled cohort allowed for the potential effect of greater 475 
magnitude of improvement in adherence to the MedDiet pattern, including within the low-fat diet group, to be 476 
explored. We also demonstrated that there were no significant differences in access to other health services or 477 
changes in types of medication or supplements taken between the groups, except for a reduction in use of β-478 
blockers in the MedDiet group. Finally, intention-to-treat analyses were performed which meant that dropouts 479 
were accounted for in all analyses. 480 




This study was however limited by the small size of a preliminary cohort of AUSMED participants, and hence 482 
was underpowered. Based on the results in these patients, the reverse power calculations which were performed 483 
for novel markers adiponectin and MDA estimated that a sample size double and close to seven times that of 484 
the current sample would be required to detect a significant effect of the ad libitum MedDiet compared to low-485 
fat diet on these markers respectively in a CHD patient setting. These results will inform future studies and 486 
analyses. The patients recruited in this study represent a lower proportion of females and are potentially more 487 
health conscious/motivated than ACS patients in the broader Australian population (64), which may impact 488 
the generalisability of the results. Nonetheless, the results of this study may be generalisable to other non-489 
Mediterranean, multicultural populations. Finally, whilst Hologic DXA measurement for VAT and SAT area 490 
are validated, they provide an estimate only.  491 
 492 
Conclusions 493 
In a small cohort of Australian patients with CHD a 6-month ad libitum MedDiet nor low-fat diet intervention 494 
led to significant improvement in adiponectin or plasma MDA levels. A lack of significant change in weight 495 
and trends for improved body fat and waist circumference assists to discount the continued misconception that 496 
a diet high in healthy fats, such is the MedDiet, leads to weight or fat gain. Greater improvement in MedDiet 497 
adherence was associated with lower waist circumference, however, this was associated with lower SAT and 498 
not VAT area, which was unexpected and may explain a lack of significant effect on measured cardiometabolic 499 
risk markers. Future studies are needed in larger cohorts. Nonetheless, in CHD patients taking intensive 500 
medications, significant clinical effects of the MedDiet on these markers may require adjunct exercise 501 
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